AB 609

This bill prevents health care entities and credentialing boards from

discriminating or retaliating against health care providers for ordering innovative

therapies or novel therapies if certain conditions are met, including: 1) the health

care provider orders the therapy based on his or her assessment of the patient and

any available clinical data supporting the therapy; 2) the patient requests the

innovative therapy or novel therapy; and 3) the ordered therapy, if the therapy is a

drug, device, or biological product, is either approved or authorized for emergency

use by the federal Food and Drug Administration. Further, this bill prevents any

health care entity or credentialing board from restricting any health care provider

from informing a patient of any innovative or novel therapy that may potentially

benefit the patient. The protections provided under the bill do not apply to a health

care provider who orders any drug, device, or biological product that is intended to

delay or suppress pubertal development in a minor for the purpose of assisting the

minor with a gender transition.